-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In August, major pharmaceutical companies intensively disclosed their semi-annual performance reports for 2022.
After sorting out the semi-annual reports, it was found that many pharmaceutical companies stated in their semi-annual reports that innovative drugs began to contribute to performance and realize value
.
Innovative drugs have begun to contribute to performance (Source: Pharmaceutical Network) For example, Kelun Pharmaceutical stated in its mid-year report that in addition to the large volume of generic drugs, the company has also ushered in a new growth point, that is, innovative drug research and development has begun to contribute revenue
.
The company clearly disclosed in the interim report: "The company has reached a cooperation agreement with MSD on innovative R&D projects and a paid exclusive license.
In the first half of 2022, Colun Botai recognized a revenue of RMB 370 million for MSD, and the increase is attributable to the parent company.
Net profit was RMB 160 million
.
” According to the data, Kelun Pharmaceutical achieved operating income of RMB 9.
125 billion in the first half of the year, a year-on-year increase of 10.
84%; net profit attributable to shareholders of listed companies was RMB 868 million, a year-on-year increase of 76.
15%
.
Kelun Pharmaceuticals said that there are currently 33 research projects in Kelun’s innovation pipeline (11 innovative small molecules and 22 biotech drugs), mainly on tumors, and also in the fields of autoimmunity, anesthesia and analgesia, cardiovascular and other diseases.
, forming disease clusters and product iteration advantages
.
At present, there are 14 clinical projects in the innovative clinical research stage, 4 projects in the preclinical development stage, and 15 projects in the drug discovery stage
.
In addition to Kelun Pharmaceuticals, Hansoh Pharma also stated in this year's semi-annual report that Hansoh Pharma maintained steady growth in performance in the first half of the year, with revenue of approximately RMB 4.
434 billion, of which revenue from innovative drugs was approximately RMB 2.
321 billion, a year-on-year increase.
About 84.
8%, the proportion of innovative drugs in revenue has risen sharply from about 28.
5% in the same period in 2021 to about 52.
3%
.
Innovative drugs Hansoh Xinfu (flumatinib mesylate tablets), Fulaimei (polyethylene glycol loxenatide injection), Mailingda (morpholinidazole and sodium chloride injection), etc.
good growth
.
Hansoh Pharma stated that among the 6 innovative drugs that Hansoh Pharma has launched in the first half of this year, 5 innovative drugs including Amelax, Hengmu, Hansoh, Fulaimei and Meilingda have been successfully commercialized
.
Thanks to the outstanding performance of 5 innovative drugs, Hansoh Pharma's innovative transformation has achieved phased success, and innovative drugs will drive the company's sustainable growth in the future
.
It is reported that Hansoh Pharma is currently conducting more than 40 innovative drug clinical trials, from more than 25 innovative drug projects in different clinical stages, covering five major indications: anti-tumor, central nervous system, anti-infection, metabolism, and autoimmunity.
.
In the first half of 2022, there are 3 self-developed projects and 1 BD project for newly entered clinical projects
.
In addition, Sino Biopharma also stated in its 2022 interim performance report that new products, innovative drugs, and oncology drugs have become the company's second growth curve
.
Among them, innovative drug revenue totaled 3.
49 billion yuan, a year-on-year increase of 14.
2%, accounting for 22.
9% of revenue
.
Sino Biopharma expects that by 2030, the proportion of revenue from innovative drugs will increase to 60%
.
It is reported that, driven by huge investment in research and development, Zhongsheng Pharma has obtained 17 listing approvals and 24 clinical approvals in the first half of the year, of which 17 are Class I innovative drug research projects, involving 8 Class I innovative products
.
It is understood that in recent years, China's pharmaceutical industry has increased investment in research and development, and traditional pharmaceutical companies and innovative pharmaceutical companies have carried out innovative drug research and development in line with international standards, driving the rapid development of the overall technical level of the pharmaceutical industry
.
According to the industry, R&D is the cornerstone of the development of innovative drug companies and also the core competitiveness of them
.
The pharmaceutical industry is a technology-intensive industry with short product life cycles and rapid technological iterative upgrades.
In order to maintain a competitive advantage, innovative drug companies continue to reserve and expand R&D pipeline products, enhance the depth and breadth of R&D, and provide guarantee for continuous growth and enhancement of core competitiveness
.
From the perspective of the above three pharmaceutical companies, Kelun Pharmaceutical invested 843 million yuan in research and development in the first half of this year, a year-on-year increase of 3.
64%, accounting for 9.
24% of sales revenue
.
It is reported that since 2013, the company has invested more than 9 billion yuan in R&D and innovation
.
Hansoh Pharma invested approximately RMB 739 million in research and development in the first half of the year, accounting for approximately 16.
7% of its revenue, maintaining a sustained growth trend
.
The research and development expenditure of Sino Biopharmaceuticals is about 2.
192 billion yuan, accounting for about 14.
4% of the revenue
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
After sorting out the semi-annual reports, it was found that many pharmaceutical companies stated in their semi-annual reports that innovative drugs began to contribute to performance and realize value
.
Innovative drugs have begun to contribute to performance (Source: Pharmaceutical Network) For example, Kelun Pharmaceutical stated in its mid-year report that in addition to the large volume of generic drugs, the company has also ushered in a new growth point, that is, innovative drug research and development has begun to contribute revenue
.
The company clearly disclosed in the interim report: "The company has reached a cooperation agreement with MSD on innovative R&D projects and a paid exclusive license.
In the first half of 2022, Colun Botai recognized a revenue of RMB 370 million for MSD, and the increase is attributable to the parent company.
Net profit was RMB 160 million
.
” According to the data, Kelun Pharmaceutical achieved operating income of RMB 9.
125 billion in the first half of the year, a year-on-year increase of 10.
84%; net profit attributable to shareholders of listed companies was RMB 868 million, a year-on-year increase of 76.
15%
.
Kelun Pharmaceuticals said that there are currently 33 research projects in Kelun’s innovation pipeline (11 innovative small molecules and 22 biotech drugs), mainly on tumors, and also in the fields of autoimmunity, anesthesia and analgesia, cardiovascular and other diseases.
, forming disease clusters and product iteration advantages
.
At present, there are 14 clinical projects in the innovative clinical research stage, 4 projects in the preclinical development stage, and 15 projects in the drug discovery stage
.
In addition to Kelun Pharmaceuticals, Hansoh Pharma also stated in this year's semi-annual report that Hansoh Pharma maintained steady growth in performance in the first half of the year, with revenue of approximately RMB 4.
434 billion, of which revenue from innovative drugs was approximately RMB 2.
321 billion, a year-on-year increase.
About 84.
8%, the proportion of innovative drugs in revenue has risen sharply from about 28.
5% in the same period in 2021 to about 52.
3%
.
Innovative drugs Hansoh Xinfu (flumatinib mesylate tablets), Fulaimei (polyethylene glycol loxenatide injection), Mailingda (morpholinidazole and sodium chloride injection), etc.
good growth
.
Hansoh Pharma stated that among the 6 innovative drugs that Hansoh Pharma has launched in the first half of this year, 5 innovative drugs including Amelax, Hengmu, Hansoh, Fulaimei and Meilingda have been successfully commercialized
.
Thanks to the outstanding performance of 5 innovative drugs, Hansoh Pharma's innovative transformation has achieved phased success, and innovative drugs will drive the company's sustainable growth in the future
.
It is reported that Hansoh Pharma is currently conducting more than 40 innovative drug clinical trials, from more than 25 innovative drug projects in different clinical stages, covering five major indications: anti-tumor, central nervous system, anti-infection, metabolism, and autoimmunity.
.
In the first half of 2022, there are 3 self-developed projects and 1 BD project for newly entered clinical projects
.
In addition, Sino Biopharma also stated in its 2022 interim performance report that new products, innovative drugs, and oncology drugs have become the company's second growth curve
.
Among them, innovative drug revenue totaled 3.
49 billion yuan, a year-on-year increase of 14.
2%, accounting for 22.
9% of revenue
.
Sino Biopharma expects that by 2030, the proportion of revenue from innovative drugs will increase to 60%
.
It is reported that, driven by huge investment in research and development, Zhongsheng Pharma has obtained 17 listing approvals and 24 clinical approvals in the first half of the year, of which 17 are Class I innovative drug research projects, involving 8 Class I innovative products
.
It is understood that in recent years, China's pharmaceutical industry has increased investment in research and development, and traditional pharmaceutical companies and innovative pharmaceutical companies have carried out innovative drug research and development in line with international standards, driving the rapid development of the overall technical level of the pharmaceutical industry
.
According to the industry, R&D is the cornerstone of the development of innovative drug companies and also the core competitiveness of them
.
The pharmaceutical industry is a technology-intensive industry with short product life cycles and rapid technological iterative upgrades.
In order to maintain a competitive advantage, innovative drug companies continue to reserve and expand R&D pipeline products, enhance the depth and breadth of R&D, and provide guarantee for continuous growth and enhancement of core competitiveness
.
From the perspective of the above three pharmaceutical companies, Kelun Pharmaceutical invested 843 million yuan in research and development in the first half of this year, a year-on-year increase of 3.
64%, accounting for 9.
24% of sales revenue
.
It is reported that since 2013, the company has invested more than 9 billion yuan in R&D and innovation
.
Hansoh Pharma invested approximately RMB 739 million in research and development in the first half of the year, accounting for approximately 16.
7% of its revenue, maintaining a sustained growth trend
.
The research and development expenditure of Sino Biopharmaceuticals is about 2.
192 billion yuan, accounting for about 14.
4% of the revenue
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
